REDWOOD CITY, Calif., Jan. 29 /PRNewswire-FirstCall/ -- Maxygen, Inc. , a biotechnology company focused on the development of improved protein drugs, will host a conference call to discuss the company’s fourth quarter and year end 2007 financial results at 11:30 a.m. ET (8:30 a.m. PT) on Tuesday, February 12, 2008. Russell Howard, Maxygen’s chief executive officer, will host the call. A press release announcing Maxygen’s fourth quarter and 2007 financial results will be issued that same day at approximately 9:00 a.m. ET.
The call will include discussion of non-GAAP financial measures. Reconciliation of the non-GAAP financial measures to the most directly applicable GAAP measures can be found in the press release announcing Maxygen’s fourth quarter and 2007 financial results. This press release will be available February 12, 2008 on Maxygen’s website at http://www.maxygen.com/news.php.
Participants in the U.S. can access the call by dialing 866.825.3209 and using the passcode 31366535. International participants can dial 617.213.8061 and use the same passcode. A live webcast of the conference call will be available at http://www.maxygen.com/webcasts.
A telephone replay of the conference call will be available until March 12, 2008. To access the replay, please call 888.286.8010 (U.S.) or 617.801.6888 (international) and use the passcode 60709469. An archived version of the webcast will be available until March 12, 2008 at http://www.maxygen.com/webcasts.
About Maxygen
Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. We look for opportunities where our proprietary protein modification technologies can address significant therapeutic needs. Our lead program, MAXY-G34, is designed to be an improved version of G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in our pipeline is a novel Factor VIIa for the treatment of hemophilia. Maxygen’s approach to drug discovery and development may allow us to leverage the established development and regulatory paths of approved drugs. We believe this advantage translates to a greater chance of successfully bringing important new drugs to market. http://www.maxygen.com
CONTACT: Michele Boudreau, Investor and Public Relations of Maxygen, Inc.,
+1-650-279-2088, michele.boudreau@maxygen.com
Web site: http://www.maxygen.com/
